CTLA4 and neoplasm: The differential role of these RT doses and fractionation regimens in combination with anti-CTLA-4 mAb, in generating systemic anti-tumor immunity, is particularly interesting, given that each of these radiotherapy schedules, were equally effective in delaying the growth of the irradiated primary tumors [25].